However, the benefit of these traditional HF therapies in patients with HF from cardiac amyloidosis is unclear.Objective:The aim of this study was to evaluate the safety and efficacy of traditional HF therapies in patients with cardiac amyloidosis and HF with reduced ejection fraction (HFrEF) or ...
While results from randomized clinical trials in patients with HFrEF, with or without diabetes, revealed the benefits of SGLT2 inhibitors without prohibitive safety concerns with prevalent baseline use of medications used to treat HF,14-17 efficacy and safety data from trials of a broader population...